Project Grant R01MH134923

Award Date 7/8/24
Completion Date 2/28/29
Dollars Obligated $2.4M
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $836,344 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the relationship between neurovascular dysfunction and neuroprogression in early-course psychosis. The key objectives are to: 1) link ex vivo blood-brain barrier (BBB) dysfunction to neuroprogression in early-course...
This federal Project Grant award of $831,180 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support the "PSYCHEMERGE: ADVANCING PRECISION PSYCHIATRY" research project led by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The key products and services to be delivered through this 5-year grant, which begins on September 1, 2024, include: Developing a nationwide federated...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $908,174 to The Lieber Institute for Brain Development to conduct research aimed at understanding the cellular and molecular mechanisms underlying schizophrenia. The primary objectives of this 5-year research project are to: 1) Replicate and expand upon previous findings linking specific cellular phenotypes derived from patient-derived...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $129,288 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) from August 1, 2024 to July 31, 2026. The grant supports the development of novel statistical methods and analytical resources for fine-mapping genetic variants associated with psychiatric disorders, with a focus on incorporating...
This $2,173,794 federal project grant award, provided by the National Institute on Aging under the Aging Research program (CFDA 93.866), supports research to investigate the potential for adult hippocampal neurogenesis (AHN) and brain-derived neurotrophic factor (BDNF) to enhance resilience to Alzheimer's disease (AD). The project aims to: 1) explore the mechanisms by which AHN cooperates with BDNF and test whether improving both can ameliorate cognitive dysfunction in tauopathy models; 2)...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to characterize the interactions between the activity-regulated cytoskeletal-associated protein (Arc) and the endocytic machinery involved in the internalization of AMPA receptors. The $328,000 award to the University of Texas Southwestern Medical Center will utilize biochemical, biophysical, and fluorescence-based imaging approaches...
This K01 career development award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will provide $183,663 in funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), over a 4-year period from September 1, 2024 to August 31, 2028. The primary aim of this grant is to enable the awardee to receive extensive training and conduct in-depth analyses to integrate common, rare, and structural...
This $811,404 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports a computational psychiatry research project focused on understanding the neural circuit mechanisms underlying anticipatory anhedonia in schizophrenia. The primary objectives are to: 1) establish the relationship between anticipatory value computation and anhedonia traits in a large online sample, 2) identify the neural circuitry involved...
This Project Grant award with ID R21MH136525 was provided by the National Institute of Mental Health (NIMH) under the federal Mental Health Research Grants program (CFDA 93.242). The $246,000 grant supports research to investigate the relationship between age-dependent dysfunction in the dentate gyrus (DG) region of the hippocampus and the development of psychosis, including symptoms associated with schizophrenia. The key objectives are to: (i) determine how gradual suppression of DG activity...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $156,656 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct advanced functional MRI (fMRI) studies of cerebral cortical layers in the human brain. The research aims to validate the use of "linescan fMRI," a high-resolution technique that can map brain activity across individual...

This federal Project Grant award of $2,354,604.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to explore the role of the ARC protein complex in improving cognitive deficits in psychotic disorders. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct a comprehensive research program to:

  1. Derive a quantitative structure-activity relationship to optimize the enhancement of ARC expression using chemical synthesis and high-content neuronal imaging.
  2. Profile a focused collection of lurasidone derivatives to evaluate their impact on dendritic spine density and cellular phenotypes in human iPSC-derived cortical neurons and cerebral organoids.
  3. Systematically characterize iPSC-derived neurons from first-episode schizophrenia patients to provide mechanistic insights into ARC and cellular phenotypes that correlate with cognitive enhancement and patient response to lurasidone.

The project, spanning from July 2024 to February 2029, seeks to advance the understanding of ARC's role in neuroplasticity and develop novel pharmacological probes and iPSC models to explore the neural substrates underlying cognitive deficits in psychotic disorders.

Generated 6/10/25, 4:12 AM